niclosamide has been researched along with Metastase in 8 studies
Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48)
niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Niclosamide reduces the growth of colorectal cancer cells by targeting several intracellular signalling pathways, including the β-catenin-dependent WNT signalling pathway." | 6.61 | New insights into niclosamide action: autophagy activation in colorectal cancer. ( Newton, PT, 2019) |
| "The potency of niclosamide on breast cancer was assessed in vitro and in vivo." | 5.40 | The anthelmintic drug niclosamide induces apoptosis, impairs metastasis and reduces immunosuppressive cells in breast cancer model. ( Li, D; Liu, L; Song, X; Wang, N; Wei, Y; Xia, Y; Xiong, Y; Yan, Y; Ye, T; Yu, L; Zeng, J; Zhang, L; Zhu, Y, 2014) |
| "Niclosamide was given three-times-daily (TID) at the following dose-levels: 500, 1000 or 1500mg." | 2.87 | A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. ( Cheng, HH; Dumpit, RF; Gulati, R; Haugk, K; Maes, JL; McCune, JS; McKiernan, JS; Montgomery, B; Nelson, PS; Plymate, SR; Schweizer, MT; Yu, EY, 2018) |
| "Niclosamide reduces the growth of colorectal cancer cells by targeting several intracellular signalling pathways, including the β-catenin-dependent WNT signalling pathway." | 2.61 | New insights into niclosamide action: autophagy activation in colorectal cancer. ( Newton, PT, 2019) |
| "Niclosamide is an oral chlorinated salicylanilide antihelminthic agent with potential anticancer activity suggested in several cancer types, however, its anticancer action and likely molecular mechanism in malignant oral cells remain unclear." | 1.48 | The Antihelminthic Niclosamide Inhibits Cancer Stemness, Extracellular Matrix Remodeling, and Metastasis through Dysregulation of the Nuclear β-catenin/c-Myc axis in OSCC. ( Chen, XY; Fu, LQ; Wang, LH; Xu, M; Yang, F, 2018) |
| "The potency of niclosamide on breast cancer was assessed in vitro and in vivo." | 1.40 | The anthelmintic drug niclosamide induces apoptosis, impairs metastasis and reduces immunosuppressive cells in breast cancer model. ( Li, D; Liu, L; Song, X; Wang, N; Wei, Y; Xia, Y; Xiong, Y; Yan, Y; Ye, T; Yu, L; Zeng, J; Zhang, L; Zhu, Y, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Dimri, S | 1 |
| Malhotra, R | 1 |
| Shet, T | 1 |
| Mokal, S | 1 |
| Gupta, S | 1 |
| De, A | 1 |
| Chien, MH | 1 |
| Ho, YC | 1 |
| Yang, SF | 1 |
| Yang, YC | 1 |
| Lai, SY | 1 |
| Chen, WS | 1 |
| Chen, MJ | 1 |
| Yeh, CB | 1 |
| Schweizer, MT | 1 |
| Haugk, K | 1 |
| McKiernan, JS | 1 |
| Gulati, R | 1 |
| Cheng, HH | 1 |
| Maes, JL | 1 |
| Dumpit, RF | 1 |
| Nelson, PS | 1 |
| Montgomery, B | 1 |
| McCune, JS | 1 |
| Plymate, SR | 1 |
| Yu, EY | 1 |
| Wang, LH | 1 |
| Xu, M | 1 |
| Fu, LQ | 1 |
| Chen, XY | 1 |
| Yang, F | 1 |
| Newton, PT | 1 |
| Ye, T | 1 |
| Xiong, Y | 1 |
| Yan, Y | 1 |
| Xia, Y | 1 |
| Song, X | 1 |
| Liu, L | 1 |
| Li, D | 1 |
| Wang, N | 1 |
| Zhang, L | 1 |
| Zhu, Y | 1 |
| Zeng, J | 1 |
| Wei, Y | 1 |
| Yu, L | 1 |
| Ippolito, JE | 1 |
| Brandenburg, MW | 1 |
| Ge, X | 1 |
| Crowley, JR | 1 |
| Kirmess, KM | 1 |
| Som, A | 1 |
| D'Avignon, DA | 1 |
| Arbeit, JM | 1 |
| Achilefu, S | 1 |
| Yarasheski, KE | 1 |
| Milbrandt, J | 1 |
| Pan, JX | 1 |
| Ding, K | 1 |
| Wang, CY | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Study of Niclosamide in Combination With Enzalutamide in Men With Castration-Resistant Prostate Cancer[NCT02532114] | Phase 1 | 5 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for niclosamide and Metastase
| Article | Year |
|---|---|
New insights into niclosamide action: autophagy activation in colorectal cancer.
Topics: Animals; Autophagic Cell Death; Colorectal Neoplasms; Humans; Neoplasm Metastasis; Niclosamide; Wnt | 2019 |
Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Humans; Mechani | 2012 |
1 trial available for niclosamide and Metastase
| Article | Year |
|---|---|
A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Proliferat | 2018 |
5 other studies available for niclosamide and Metastase
| Article | Year |
|---|---|
Noncanonical pS727 post translational modification dictates major STAT3 activation and downstream functions in breast cancer.
Topics: Animals; Anthelmintics; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; Mice | 2020 |
Niclosamide, an oral antihelmintic drug, exhibits antimetastatic activity in hepatocellular carcinoma cells through downregulating twist-mediated CD10 expression.
Topics: Administration, Oral; Anthelmintics; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Dow | 2018 |
The Antihelminthic Niclosamide Inhibits Cancer Stemness, Extracellular Matrix Remodeling, and Metastasis through Dysregulation of the Nuclear β-catenin/c-Myc axis in OSCC.
Topics: Aldehyde Dehydrogenase; Anthelmintics; Antineoplastic Agents; Apoptosis; beta Catenin; Carcinoma, Sq | 2018 |
The anthelmintic drug niclosamide induces apoptosis, impairs metastasis and reduces immunosuppressive cells in breast cancer model.
Topics: Animals; Anthelmintics; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell M | 2014 |
Extracellular pH Modulates Neuroendocrine Prostate Cancer Cell Metabolism and Susceptibility to the Mitochondrial Inhibitor Niclosamide.
Topics: Acids; Cell Line, Tumor; Energy Metabolism; Glucose; Glycolysis; Humans; Hydrogen-Ion Concentration; | 2016 |